サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1636058

デュシェンヌ型筋ジストロフィー（DMD）治療薬市場：製品タイプ別、治療アプローチ別、エンドユーザー別、地域別、2025-2033年

Duchenne Muscular Dystrophy Drugs Market by Product Type (Corticosteroids, Pain Management Drugs), Therapeutic Approach (Mutation Suppression, Exon Skipping, Steroid Therapy), End User (Hospitals, Clinics, Home Care Settings), and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 143 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
デュシェンヌ型筋ジストロフィー（DMD）治療薬市場：製品タイプ別、治療アプローチ別、エンドユーザー別、地域別、2025-2033年
出版日: 2025年01月10日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

デュシェンヌ型筋ジストロフィー（DMD）治療薬市場の世界市場規模は2024年に25億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに59億米ドルに達し、2025～2033年の成長率（CAGR）は9.46％になると予測しています。大衆におけるデュシェンヌ型筋ジストロフィーの有病率の上昇、新製品の承認・上市数の増加、良好な償還政策を提供する有利な政府の取り組み、標的特異的治療の促進などが、市場を牽引する主な要因となっています。

デュシェンヌ型筋ジストロフィー（DMD）治療薬は、主に男性が罹患し、まれに女性も罹患する進行性の重篤なX連鎖性遺伝性筋ジストロフィーの治療に使用されます。この疾患の症状には、歩行困難、起立困難、座位困難、言語障害などがあり、骨格筋や心筋の萎縮としても知られる筋力低下や筋力低下が進行します。DMD治療薬は、心筋と骨格筋を標的とすることにより、患者の心臓と肺の機能を高める。ジストロフィンは筋肉の完全性を維持する重要なタンパク質であり、その欠損や異常がDMDの原因となります。そのため、DMDの治療薬のほとんどはジストロフィンに基づくものです。DMDの他の主な治療戦略には、ジストロフィンの産生を回復させる特定の変異に関連した遺伝子治療、膜の安定化または代償タンパク質のアップレギュレーション、炎症カスケードの減少および/または筋再生の促進などがあります。

デュシェンヌ型筋ジストロフィー（DMD）治療薬市場傾向：

主要メーカーによる新製品の承認・上市数の増加は、市場の成長を促す重要な要因です。これは、大衆の間でデュシェンヌ型筋ジストロフィーの罹患率が増加していることに起因しています。これに伴い、臨床試験が大幅に増加し、強力なパイプラインが存在することも市場に弾みをつけています。さらに、診断における絶え間ない技術革新による変異特異的治療の登場も、市場にプラスの影響を与えています。このほか、乳幼児、女性、歩行困難な患者など、十分な治療を受けていないカテゴリーに対するDMDの正確な診断と治療に焦点を当てた広範な研究開発（R&D）活動も市場を後押ししています。しかし、薬剤の臨床効果を調べるための標準化された手順の不足、診断と予測の遅れ、遺伝子治療薬のコスト上昇が、市場の成長抑制要因として作用しています。それとは反対に、良好な償還政策を提供する有利な政府のイニシアチブは、標的特異的治療の促進とともに、市場の成長に寄与しています。市場に有利な成長機会をもたらすその他の要因としては、急速な都市化、医療インフラの改善、製品のプレミアム化の新たな動向、大衆の可処分所得の増加などが挙げられます。

本レポートで扱う主な質問

  • 世界のデュシェンヌ型筋ジストロフィー（DMD）治療薬市場の市場規模は？
  • 2025-2033年における世界のデュシェンヌ型筋ジストロフィー（DMD）治療薬市場の予想成長率は？
  • 世界のデュシェンヌ型筋ジストロフィー（DMD）治療薬市場を牽引する主要因は何か？
  • 世界のデュシェンヌ型筋ジストロフィー（DMD）治療薬市場に対するCOVID-19の影響は？
  • 世界のデュシェンヌ型筋ジストロフィー（DMD）治療薬市場の製品タイプ別内訳は？
  • 治療アプローチに基づく世界のデュシェンヌ型筋ジストロフィー（DMD）治療薬市場の内訳は？
  • 世界のデュシェンヌ型筋ジストロフィー（DMD）治療薬市場のエンドユーザー別の内訳は？
  • デュシェンヌ型筋ジストロフィー（DMD）治療薬市場の世界における主要地域は？
  • 世界のデュシェンヌ型筋ジストロフィー（DMD）治療薬市場における主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のデュシェンヌ型筋ジストロフィー（DMD）治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品タイプ別

  • コルチコステロイド
    • 市場動向
    • 主要セグメント
      • プレドニゾロン
      • プレドニゾン
      • デフラザコート
    • 市場予測
  • 疼痛管理薬
    • 市場動向
    • 市場予測

第7章 市場内訳：治療アプローチ別

  • 突然変異の抑制
    • 市場動向
    • 市場予測
  • エクソンスキッピング
    • 市場動向
    • 市場予測
  • ステロイド療法
    • 市場動向
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • クリニック
    • 市場動向
    • 市場予測
  • 在宅環境
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第10章 促進要因・抑制要因・機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • FibroGen Inc.
    • Italfarmaco S.p.A.
    • NS Pharma Inc.（Nippon Shinyaku Co. Ltd.）
    • PTC Therapeutics Inc.
    • Santhera Pharmaceuticals
    • Sarepta Therapeutics Inc.
図表

List of Figures

  • Figure 1: Global: Duchenne Muscular Dystrophy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Product Type (in %), 2024
  • Figure 5: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Therapeutic Approach (in %), 2024
  • Figure 6: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: North America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: North America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: United States: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: United States: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Canada: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Canada: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: China: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: China: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Japan: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Japan: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: India: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: India: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: South Korea: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: South Korea: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Australia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Australia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Indonesia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Indonesia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Europe: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Europe: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Germany: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Germany: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: France: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: France: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: United Kingdom: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: United Kingdom: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Italy: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Italy: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Spain: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Spain: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Russia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Russia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Latin America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Latin America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Brazil: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Brazil: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Mexico: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Mexico: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Breakup by Country (in %), 2024
  • Figure 72: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Global: Duchenne Muscular Dystrophy Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 74: Global: Duchenne Muscular Dystrophy Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Duchenne Muscular Dystrophy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Duchenne Muscular Dystrophy Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
  • Table 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Therapeutic Approach (in Million USD), 2025-2033
  • Table 4: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Duchenne Muscular Dystrophy Drugs Market: Competitive Structure
  • Table 7: Global: Duchenne Muscular Dystrophy Drugs Market: Key Players
目次
Product Code: SR112025A6715

The global Duchenne muscular dystrophy drugs market size reached USD 2.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.9 Billion by 2033, exhibiting a growth rate (CAGR) of 9.46% during 2025-2033. The rising prevalence of Duchenne muscular dystrophy among the masses, the increasing number of new product approvals and launches, and favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, represent some of the key factors driving the market.

Duchenne muscular dystrophy (DMD) drugs are utilized to treat a severe X-linked genetic disorder of a progressive form of muscular dystrophy that primarily affects the male population, and rarely females as well. The symptoms of this disorder include difficulty walking, standing, and sitting, as well as speech difficulties, which can result in progressive weakness and loss, also known as atrophy, in the skeletal and heart muscles. The DMD drugs enhance cardiac and pulmonary functions in patients by targeting cardiac and skeletal muscles. Dystrophin is a key protein that maintains muscular integrity, and its absence or abnormality causes DMD. As a result, most of the drugs for the treatment of DMD are dystrophin-based. Some of the other primary treatment strategies for DMD also include genetic therapies linked to specific mutations which restore dystrophin production, membrane stabilization or upregulation of compensatory proteins, and a reduction of the inflammatory cascade and/or enhancement of muscle regeneration.

Duchenne Muscular Dystrophy Drugs Market Trends:

The rising number of new product approvals and launches by the major manufacturers is a significant factor driving the growth of the market. This can be attributed to the growing incidences of Duchenne muscular dystrophy among the masses. In line with this, a considerable rise in clinical trials, along with the presence of strong pipeline of products, is providing an impetus to the market. Moreover, the advent of mutation-specific therapies due to continual innovations in diagnostics is also impacting the market positively. Besides this, extensive research and development (R&D) activities focusing on accurate diagnosis and treatment of DMD for underserved categories, such as infants, females, and nonambulant patients, are propelling the market. However, the shortage of standardized procedures for the examination of the clinical efficacy of drugs, delayed diagnosis and prediction, and the rising costs of genetic therapeutics are acting as growth-restraining factors for the market. On the contrary, favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, are contributing to the market growth. Some of the other factors creating lucrative growth opportunities in the market include rapid urbanization, improving medical infrastructure, emerging trend of product premiumization, and inflating disposable incomes of the masses.

Key Market Segmentation:

Product Type Insights:

  • Corticosteroids
  • Prednisolone
  • Prednisone
  • Deflazacort
  • Pain Management Drugs

Therapeutic Approach Insights:

  • Mutation Suppression
  • Exon Skipping
  • Steroid Therapy

End User Insights:

  • Hospitals
  • Clinics
  • Home Care Settings

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for Duchenne muscular dystrophy drugs. Some of the factors driving the North America Duchenne muscular dystrophy drugs market include the rising number of new product approvals and launches, continual improvements in medical infrastructure, and the presence of several key players in the country.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global Duchenne muscular dystrophy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include FibroGen Inc., Italfarmaco S.p.A., NS Pharma Inc. (Nippon Shinyaku Co. Ltd.), PTC Therapeutics Inc., Santhera Pharmaceuticals, Sarepta Therapeutics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global Duchenne muscular dystrophy drugs market?
  • 2. What is the expected growth rate of the global Duchenne muscular dystrophy drugs market during 2025-2033?
  • 3. What are the key factors driving the global Duchenne muscular dystrophy drugs market?
  • 4. What has been the impact of COVID-19 on the global Duchenne muscular dystrophy drugs market?
  • 5. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the product type?
  • 6. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the therapeutic approach?
  • 7. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the end user?
  • 8. What are the key regions in the global Duchenne muscular dystrophy drugs market?
  • 9. Who are the key players/companies in the global Duchenne muscular dystrophy drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Duchenne Muscular Dystrophy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Corticosteroids
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Prednisolone
      • 6.1.2.2 Prednisone
      • 6.1.2.3 Deflazacort
    • 6.1.3 Market Forecast
  • 6.2 Pain Management Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Therapeutic Approach

  • 7.1 Mutation Suppression
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Exon Skipping
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Steroid Therapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Home Care Settings
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 FibroGen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Italfarmaco S.p.A.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 PTC Therapeutics Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Santhera Pharmaceuticals
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Sarepta Therapeutics Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.